Cargando…

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer

Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of RAS mutant clones in plasma has been more rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raimondi, Cristina, Nicolazzo, Chiara, Belardinilli, Francesca, Loreni, Flavia, Gradilone, Angela, Mahdavian, Yasaman, Gelibter, Alain, Giannini, Giuseppe, Cortesi, Enrico, Gazzaniga, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357143/ https://www.ncbi.nlm.nih.gov/pubmed/30621206 http://dx.doi.org/10.3390/cancers11010042

Ejemplares similares

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

Letter to the Editor: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”
por: Nicolazzo, Chiara, et al.
Publicado: (2017)

EpCAM(low) Circulating Tumor Cells: Gold in the Waste
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study
por: Nicolazzo, Chiara, et al.
Publicado: (2022)

Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments
por: Nicolazzo, Chiara, et al.
Publicado: (2021)

Molecular markers in circulating tumour cells from metastatic colorectal cancer patients
por: Gazzaniga, Paola, et al.
Publicado: (2010)

The effects of mutant Ras proteins on the cell signalome
por: Takács, Tamás, et al.
Publicado: (2020)

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS
por: Ilter, Metehan, et al.
Publicado: (2022)

Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth
por: Shin, Seung-Min, et al.
Publicado: (2020)

Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach
por: McFall, Thomas, et al.
Publicado: (2021)

Argonaute 2 modulates EGFR–RAS signaling to promote mutant HRAS and NRAS-driven malignancies
por: Siebenaler, Ronald F, et al.
Publicado: (2022)

Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients
por: Banda, Malathi
Publicado: (2015)

Selective and noncovalent targeting of RAS mutants for inhibition and degradation
por: Teng, Kai Wen, et al.
Publicado: (2021)

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
por: Scharpf, Robert B., et al.
Publicado: (2022)

Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
por: Ferguson, Robert, et al.
Publicado: (2023)

Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer
por: Murillo, Miguel M., et al.
Publicado: (2018)

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
por: Jin, Hua, et al.
Publicado: (2019)

Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers
por: Kleiman, Laura B., et al.
Publicado: (2013)

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
por: Yang, Hang, et al.
Publicado: (2022)

Injury prevents Ras mutant cell expansion in mosaic skin
por: Gallini, Sara, et al.
Publicado: (2023)

Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal
por: Gradilone, Angela, et al.
Publicado: (2011)

Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo
por: Raimondi, Cristina, et al.
Publicado: (2014)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
por: Nichols, Robert J., et al.
Publicado: (2018)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

An unexpected new role of mutant Ras: perturbation of human embryonic development
por: Kratz, Christian P., et al.
Publicado: (2007)

Interactions Between Wildtype and Mutant Ras Genes in Lung and Skin Carcinogenesis
por: To, Minh D., et al.
Publicado: (2012)

Cytotoxicity of Simvastatin to Pancreatic Adenocarcinoma Cells Containing Mutant ras Gene
por: Ura, Hitoshi, et al.
Publicado: (1994)

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway
por: Gillies, Taryn E, et al.
Publicado: (2020)

Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer
por: Lee, Jennifer J., et al.
Publicado: (2021)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.
por: Kopreski, M. S., et al.
Publicado: (1997)

Expression, purification, crystallization and X-ray data collection for RAS and its mutants
por: Johnson, Christian W., et al.
Publicado: (2015)

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma
por: Sriskandarajah, Priya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u3tnrluvq0om3uhl0n28puukm6